🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

CSL Behring clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our USA, UK, China, Ireland and EU (CTIS) registers with CSL Behring as lead sponsor. Synced 26 Sep 2026
19Current trials
13Recruiting now
1Drug in these trials
5Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

CSL Behring is the lead sponsor of 19 current clinical trials in our USA, UK, China, Ireland and EU (CTIS) registers. 13 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are CSL300. The most-studied condition is Hemophilia B.

ClinicalTrials.gov trials by status

  • Recruiting1387%
  • Active, closed17%
  • By invitation17%

Trials by phase

  • Phase 3640%
  • Phase 2320%
  • Observational320%
  • Phase 2/317%
  • Phase 417%
  • Phase 117%
01

Clinical trials sponsored by CSL Behring

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091 · Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Phase 2 Recruiting 2026-01 Ireland, UK, USA
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360 · Sickle Cell Disease
Phase 2 Recruiting 2026-02 UK, USA
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
NCT06003387 · Hemophilia B
Phase 3 Recruiting 2024-01 USA
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961 · ClinicalTrials.gov ↗ · End Stage Kidney Disease
Drug: CSL300
Phase 2/3 Recruiting 2024-04 UK, USA, China
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849 · ClinicalTrials.gov ↗ · Sickle Cell Disease Vaso-occlusive Crisis
Phase 2 Recruiting 2025-08 UK, USA
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905 · ClinicalTrials.gov ↗ · Hemophilia B
Phase 3 Recruiting 2025-07 UK, USA
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264 · ClinicalTrials.gov ↗ · Secondary Immune Deficiency
Phase 3 Recruiting 2026-09 UK, USA
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280 · ClinicalTrials.gov ↗ · Hereditary Angioedemas
Observational Recruiting 2025-07 UK, USA
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
NCT06617897 · ClinicalTrials.gov ↗ · Acquired Fibrinogen Deficiency
Phase 3 Recruiting 2024-10 UK
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018 · ClinicalTrials.gov ↗ · Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 4 Recruiting 2019-02 USA
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
NCT07094087 · ClinicalTrials.gov ↗ · Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Phase 3 Recruiting 2025-09 USA
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
NCT06008938 · ClinicalTrials.gov ↗ · Hemophilia B
Observational Recruiting 2023-06 USA
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
NCT07619820 · ClinicalTrials.gov ↗ · End Stage Kidney Disease (ESKD)
Drug: CSL300
Phase 1 Recruiting 2026-06 China
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
NCT05962398 · ClinicalTrials.gov ↗ · Hemophilia B
Observational By invitation 2023-08 Ireland, UK, USA
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
NCT06738485 · ClinicalTrials.gov ↗ · Congenital Hemophilia A
Phase 3 Active, closed 2025-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

CSL Behring in the EU trials register (CTIS)

4 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with CSL Behring as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
2025-523793-16-00 · CTIS ↗ · Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Phase 2 Ongoing Ireland + 10 more
A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency
2025-522964-33-00 · CTIS ↗ · Respiratory Tract Diseases
Phase 4 Ongoing Denmark
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
2025-521154-42-00 · CTIS ↗ · Hemic and Lymphatic Diseases
Phase 2 Ongoing Belgium, Netherlands, France + 1 more
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis
2024-518821-13-00 · CTIS ↗ · Respiratory Tract Diseases
Phase 2 Authorised Spain, Belgium, Germany + 7 more
03

Drugs in CSL Behring trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

04

Conditions in CSL Behring trials

12 conditions
Hemophilia B4Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis1Sickle Cell Disease1End Stage Kidney Disease1Sickle Cell Disease Vaso-occlusive Crisis1Secondary Immune Deficiency1Hereditary Angioedemas1Acquired Fibrinogen Deficiency1Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1Complex Cardiovascular Surgery With Cardiopulmonary Bypass1Congenital Hemophilia A1End Stage Kidney Disease (ESKD)1
05

By trial register

RegisterTrialsRecruiting
Clinical trials in USA1211
Clinical trials in UK98
Clinical trials in China32
Clinical trials in Ireland21
EU register (CTIS)4—

A trial with sites in more than one country appears in each of those registers.

06

Other sponsors in Hemophilia B

SponsorTrials
Shanghai Xinzhi BioMed1
Shanghai RAAS Blood Products1

Sponsors with the most current trials registered for this condition.

07

Questions about CSL Behring trials

How many clinical trials does CSL Behring sponsor?

CSL Behring is the lead sponsor of 15 current trials on ClinicalTrials.gov in our USA, UK, China and Ireland registers, and 4 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are CSL Behring trials recruiting?

Yes. 13 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is CSL Behring testing?

Its current trials name 1 drug or biological as interventions. The most frequent are CSL300 (2). The number in brackets is how many of its trials name each drug.

Does CSL Behring have clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.